Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | CNR1 | P21554 | 3/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.50 |
| ▸ | GALR3 | O60755 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22894161 | 0.89 | CHRM1 (0.56) | MAPTCNR1TAAR1NPC1RAB9A | |
| SCHEMBL11526668 | 0.86 | MAPT (0.77) | MAPTCNR1NPC1RAB9ALMNA | |
| SCHEMBL26267972 | 0.85 | TAAR1 (0.60) | MAPTCNR1TAAR1GPR84RAB9A | |
| SCHEMBL27724007 | 0.83 | MAPT (0.67) | MAPTCNR1GPR84NPC1RAB9A | |
| SCHEMBL26267723 | 0.83 | MAPT (0.67) | MAPTCNR1TAAR1GPR84GALR3 | |
| SCHEMBL24756902 | 0.81 | MAPT (0.65) | MAPTCNR1TAAR1GPR84GALR3 | |
| SCHEMBL26267841 | 0.81 | MAPT (0.65) | MAPTCNR1TAAR1GPR84GALR3 | |
| SCHEMBL28625506 | 0.81 | MAPT (0.57) | MAPTCNR1TAAR1GPR84NPC1 | |
| SCHEMBL3904496 | 0.81 | L3MBTL1 (0.70) | MAPTTAAR1NPC1RAB9AKMT2A | |
| SCHEMBL248884 | 0.81 | L3MBTL1 (0.70) | MAPTTAAR1GPR84NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11696937-B2 | Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof | SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) | 2023-07-11 | — | — | US | disclosed |
| US-11696937-B2 | Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof | SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) | 2023-07-11 | — | — | US | disclosed |
| US-20210093691-A1 | Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof | SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) | 2021-04-01 | — | — | US | disclosed |
| EP-3763728-A1 | GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai LaiYi Center For Biopharmaceutical R&D Co., Ltd. (CN) | 2021-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093691-A1 | Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof | VIP, CUTA, MGAM | MAPT 3389/4885CNR1 4714/4885TAAR1 3759/4885 |
| US-11696937-B2 | Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof | VIP, CUTA, MGAM | MAPT 3389/4885CNR1 4714/4885TAAR1 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.